SAN DIEGO--(BUSINESS WIRE)--A member of the faculty at San Diego Academy of Regenerative Therapies (SDARTs) has published an important paper addressing pulmonary and respiratory therapies for patients who have suffered from the nCoV-2 Coronavirus. Robert W. Alexander, MD, DMD, FICS is the Principal Investigator for the first-in-human clinical trial described in the article.
This paper reviews many of the current issues facing survivors of moderate to severe COVID-19 infections. It explores options for a new therapeutic approach, which clearly shows promise to reverse some residual damage to the lung and gas exchange functions.
According to Dr. Alexander, “this damage represents a reasonable target for the use of cSVF (isolated Stromal Vascular Fraction cells) to help mitigate damaged gas exchange areas of the involved lung tissues, based on positive clinical experiences in COPD and IFL disease patients.”
The article “represents a promising treatment for these patients,” according to SDARTs CEO, Marcille Pilkington. “We’ve known that Adipose-derived cSVF promotes repair and regenerative effects in COPD patients. To deploy this treatment in Coronavirus survivors is truly exciting.”
The sterile, coated closed syringe microcannula systems from Tulip Medical Products, a division of Black Tie Medical, Inc., San Diego, CA, USA (the sponsor of the study) have proven to be amongst the most reliable and trusted systems available for the gentle, safe and easy access to these adipose cells and attachment media (ECM).
Dr. Robert Alexander is but one of many faculty members who have recorded extensive didactic and master class demonstrations available as part of the SDARTs online learning platform. “Unfortunately, we had to cancel this year’s global conference in San Diego due to the Pandemic,” says Marcille Pilkington. “But we’ve archived more than three years of conference video content, plus specialized compendiums, master classes and presentations from Expert Contributors, that will help doctors learn more about the evolving uses of Microfat, Nanofat, and cSVF in regenerative therapies. All of this is now available online and on-demand. We’re also in the early stage of preparations for the SDARTs 2021 Global Conference in August 2021, where we’ll present the latest in the uses of adipose therapies for COVID-19 as well as therapies for musculoskeletal applications, hair restoration, regenerative aesthetics and breast reconstruction.”
Looking ahead, Dr. Alexander’s newest article detailing the diagnostic and treatment protocol for this groundbreaking clinical trial will be published in the next edition of Stem Cell Research, scheduled for release on June 25.
Find out more about SDARTs' Online Learning Platform.
SDARTs offers training courses in surgical and office-based procedures using adipose regenerative therapies in Aesthetic Medicine, Plastic and Reconstructive Surgery, and Orthopedic Medicine and Surgery. The faculty instructs using clinically proven protocols that ensure reproducibility of outcomes.